290 related articles for article (PubMed ID: 26873727)
1. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
Schwaederle M; Parker BA; Schwab RB; Daniels GA; Piccioni DE; Kesari S; Helsten TL; Bazhenova LA; Romero J; Fanta PT; Lippman SM; Kurzrock R
Mol Cancer Ther; 2016 Apr; 15(4):743-52. PubMed ID: 26873727
[TBL] [Abstract][Full Text] [Related]
2. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach.
Kato S; Kurasaki K; Ikeda S; Kurzrock R
Oncologist; 2018 Feb; 23(2):171-178. PubMed ID: 29038235
[TBL] [Abstract][Full Text] [Related]
3. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
4. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.
Tsimberidou AM; Hong DS; Wheler JJ; Falchook GS; Janku F; Naing A; Fu S; Piha-Paul S; Cartwright C; Broaddus RR; Nogueras Gonzalez GM; Hwu P; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):145. PubMed ID: 31888672
[TBL] [Abstract][Full Text] [Related]
5. Community-driven development of a modified progression-free survival ratio for precision oncology.
Mock A; Heilig CE; Kreutzfeldt S; Huebschmann D; Heining C; Schröck E; Brors B; Stenzinger A; Jäger D; Schlenk R; Glimm H; Fröhling S; Horak P;
ESMO Open; 2019; 4(6):e000583. PubMed ID: 31798980
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
[TBL] [Abstract][Full Text] [Related]
7. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
8. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Rodon J; Soria JC; Berger R; Miller WH; Rubin E; Kugel A; Tsimberidou A; Saintigny P; Ackerstein A; Braña I; Loriot Y; Afshar M; Miller V; Wunder F; Bresson C; Martini JF; Raynaud J; Mendelsohn J; Batist G; Onn A; Tabernero J; Schilsky RL; Lazar V; Lee JJ; Kurzrock R
Nat Med; 2019 May; 25(5):751-758. PubMed ID: 31011205
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study.
Gambardella V; Lombardi P; Carbonell-Asins JA; Tarazona N; Cejalvo JM; González-Barrallo I; Martín-Arana J; Tébar-Martínez R; Viala A; Bruixola G; Hernando C; Blasco I; Papaccio F; Martínez-Ciarpaglini C; Alfaro-Cervelló C; Seda-García E; Blesa S; Chirivella I; Castillo J; Montón-Bueno JV; Roselló S; Huerta M; Pérez-Fidalgo A; Martín-Martorell P; Insa-Mollá A; Fleitas T; Rentero-Garrido P; Zúñiga-Trejos S; Cervantes A; Roda D
Br J Cancer; 2021 Oct; 125(9):1261-1269. PubMed ID: 34493820
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
11. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.
Sicklick JK; Kato S; Okamura R; Patel H; Nikanjam M; Fanta PT; Hahn ME; De P; Williams C; Guido J; Solomon BM; McKay RR; Krie A; Boles SG; Ross JS; Lee JJ; Leyland-Jones B; Lippman SM; Kurzrock R
Genome Med; 2021 Oct; 13(1):155. PubMed ID: 34607609
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.
Ibrahim T; Ahmadie A; Rassy E; Karak FE; Hanna C; Farhat F; Kattan J; Ghosn M
Bull Cancer; 2020 Apr; 107(4):410-416. PubMed ID: 32145962
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies.
Kato S; Okamura R; Sicklick JK; Daniels GA; Hong DS; Goodman A; Weihe E; Lee S; Khalid N; Collier R; Mareboina M; Riviere P; Whitchurch TJ; Fanta PT; Lippman SM; Kurzrock R
Int J Cancer; 2020 Jun; 146(12):3450-3460. PubMed ID: 31782524
[TBL] [Abstract][Full Text] [Related]
15. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.
Kato S; Kim KH; Lim HJ; Boichard A; Nikanjam M; Weihe E; Kuo DJ; Eskander RN; Goodman A; Galanina N; Fanta PT; Schwab RB; Shatsky R; Plaxe SC; Sharabi A; Stites E; Adashek JJ; Okamura R; Lee S; Lippman SM; Sicklick JK; Kurzrock R
Nat Commun; 2020 Oct; 11(1):4965. PubMed ID: 33009371
[TBL] [Abstract][Full Text] [Related]
16. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy.
Sheu T; Heymach JV; Swisher SG; Rao G; Weinberg JS; Mehran R; McAleer MF; Liao Z; Aloia TA; Gomez DR
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):850-7. PubMed ID: 25216859
[TBL] [Abstract][Full Text] [Related]
17. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.
Schwaederle M; Parker BA; Schwab RB; Fanta PT; Boles SG; Daniels GA; Bazhenova LA; Subramanian R; Coutinho AC; Ojeda-Fournier H; Datnow B; Webster NJ; Lippman SM; Kurzrock R
Oncologist; 2014 Jun; 19(6):631-6. PubMed ID: 24797821
[TBL] [Abstract][Full Text] [Related]
18. Targeting fusions for improved outcomes in oncology treatment.
Nikanjam M; Okamura R; Barkauskas DA; Kurzrock R
Cancer; 2020 Mar; 126(6):1315-1321. PubMed ID: 31794076
[TBL] [Abstract][Full Text] [Related]
19. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
20. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Massard C; Michiels S; Ferté C; Le Deley MC; Lacroix L; Hollebecque A; Verlingue L; Ileana E; Rosellini S; Ammari S; Ngo-Camus M; Bahleda R; Gazzah A; Varga A; Postel-Vinay S; Loriot Y; Even C; Breuskin I; Auger N; Job B; De Baere T; Deschamps F; Vielh P; Scoazec JY; Lazar V; Richon C; Ribrag V; Deutsch E; Angevin E; Vassal G; Eggermont A; André F; Soria JC
Cancer Discov; 2017 Jun; 7(6):586-595. PubMed ID: 28365644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
